Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
An update from LifeTech Scientific Corporation ( (HK:1302) ) is now available.
LifeTech Scientific Corporation has convened its annual general meeting for 28 May 2026 in Shenzhen, where shareholders will review and adopt the audited consolidated financial statements for the year ended 31 December 2025 and the associated directors’ and auditor’s reports. Investors will also vote on the re-election of a broad slate of executive, non-executive and independent non-executive directors, including confirming a long-serving independent director, and on re-appointing Deloitte Touche Tohmatsu as auditor, decisions that will shape the company’s governance continuity and oversight.
The meeting will further ask shareholders to grant the board a general mandate to allot, issue and deal in additional shares or convertible securities up to 20% of the existing share capital, excluding treasury shares. Approval of this mandate would give LifeTech added flexibility to raise capital, pursue strategic initiatives or incentivize staff through equity, while revoking any previous similar mandates to keep its capital-raising authority aligned with current shareholder consent.
More about LifeTech Scientific Corporation
LifeTech Scientific Corporation is a Cayman Islands-incorporated company listed in Hong Kong and based in Shenzhen, operating in the medical technology sector. The group develops and markets cardiovascular and other implantable medical devices, targeting hospitals and healthcare providers in China and international markets.
Average Trading Volume: 19,645,498
Technical Sentiment Signal: Buy
Current Market Cap: HK$9.03B
For a thorough assessment of 1302 stock, go to TipRanks’ Stock Analysis page.